CompletedPhase 3NCT05249816

Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cogna Technology Solutions LLC
Principal Investigator
Nawal Al Kaabi
Sheikh Khalifa Medical City
Intervention
NVX-CoV2373(biological)
Enrollment
1000 enrolled
Eligibility
18 years · All sexes
Timeline
20222023

Study locations (2)

Collaborators

Novavax

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05249816 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials